|
UNITED STATES |
|||
|
SECURITIES AND EXCHANGE COMMISSION |
|||
|
Washington, D.C. 20549 |
|||
|
FORM 8-K |
|||
|
CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
|||
|
May 3, 2018 |
|||
|
(Date of Report) |
|||
|
ULTRALIFE CORPORATION |
|||
|
(Exact name of registrant as specified in its charter) |
|||
|
Delaware |
000-20852 |
16-1387013 |
|
|
(State of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
2000 Technology Parkway, Newark, New York |
14513 |
||
|
(Address of principal executive offices) |
(Zip Code) |
||
|
(315) 332-7100 |
|||
|
(Registrant’s telephone number, including area code) |
|||
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
|||
|
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|||
|
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|||
|
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|||
|
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. [ ]
Emerging Growth Company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ] |
|||
|
Item 2.02 |
Results of Operations and Financial Condition |
On May 3, 2018, Ultralife Corporation issued a press release regarding the financial results for its first quarter ended April 1, 2018. A copy of this press release is attached hereto as Exhibit 99.1.
The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed as incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.
|
Item 9.01 |
Financial Statements, Pro Forma Financials and Exhibits |
(d) Exhibits.
Exhibit
|
Number |
Exhibit Description |
|
99.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: May 3, 2018 |
ULTRALIFE Corporation |
|
|
By: |
/s/ Philip A. Fain |
|
|
Philip A. Fain |
||
|
Chief Financial Officer and Treasurer |
Exhibit 99.1
|
Company Contact: Ultralife Corporation Philip A. Fain (315) 210-6110 pfain@ulbi.com |
Investor Relations Contact: LHA Jody Burfening (212) 838-3777 jburfening@lhai.com |
Ultralife Corporation Reports First Quarter Results
NEWARK, N.Y. – May 3, 2018 -- Ultralife Corporation (NASDAQ: ULBI) reported operating income of $2.4 million on revenue of $23.1 million for the first quarter ended April 1, 2018. For the first quarter of 2017, the Company reported operating income of $1.8 million on revenue of $22.0 million.
“Our first quarter results demonstrate the leveraged earnings power of our business model and the diversity of new revenue opportunities we have been cultivating,” said Michael D. Popielec, President and Chief Executive Officer. “Total Company government/defense sales grew 6% driven by strong Communications Systems shipments and total Company commercial sales grew 3% driven by higher medical sales. On the strength of 5% revenue growth, solid gross margins and disciplined expense control, operating profit grew 28% generating a 10.2% operating margin. A strong start to the year, backlog, and strict adherence to our business model parameters give us confidence that we will deliver another year of profitable growth.”
First Quarter 2018 Financial Results
Revenue was $23.1 million, an increase of $1.0 million, or 4.7%, compared to $22.0 million for the first quarter of 2017 reflecting higher medical and government/defense sales. Battery & Energy Products sales decreased $.3 million, or 1.5%, to $17.2 million compared to $17.5 million last year due primarily to timing differences in government/defense shipments, not fully offset by an 18.9% increase in medical sales. Communications Systems grew 28.3% to $5.8 million compared to $4.6 million for the same period last year reflecting shipments of our Vehicle Amplifier Adapters for the U.S. Army’s Special Force Assistance Brigades under a contract awarded in December 2017, power supplies shipments to a large global defense prime contractor, as well as a 49% year-over-year increase in shipments of core products such as our 20-watt amplifiers and universal vehicle adapters.
Gross profit was $7.3 million, or 31.6% of revenue, compared to $6.9 million, or 31.3% of revenue, for the same quarter a year ago. Battery & Energy Products’ gross margin was 29.2%, compared to 28.2% last year, and Communications Systems’ gross margin was 38.4%, compared to 43.0% last year, primarily due to product mix.
Operating expenses were $4.9 million compared to $5.0 million last year reflecting continued tight control over discretionary spending. Operating expenses were 21.4% of revenue compared to 22.9% of revenue for the year-earlier period.
Operating income was $2.4 million compared to $1.8 million last year for an operating margin of 10.2% compared to 8.4% last year.
Net income was $2.2 million, or $0.14 per share, compared to net income of $1.7 million, or $0.11 per share, for the first quarter of 2017.
About Ultralife Corporation
Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.
Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.
Conference Call Information
Ultralife will hold its first quarter earnings conference call today at 10:00 AM ET. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.
This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: potential reductions in revenues from key customers, uncertain global economic conditions and acceptance of our new products on a global basis. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.
|
ULTRALIFE CORPORATION AND SUBSIDIARIES |
|
|
CONSOLIDATED BALANCE SHEETS (Dollars in Thousands) |
|
|
(Unaudited) |
|
April 1, |
December 31, |
|||||||
|
2018 |
2017 |
|||||||
| ASSETS | ||||||||
|
Current Assets: |
||||||||
|
Cash |
$ | 18,330 | $ | 18,330 | ||||
|
Trade Accounts Receivable, Net |
15,730 | 14,657 | ||||||
|
Inventories |
26,961 | 26,326 | ||||||
|
Prepaid Expenses and Other Current Assets |
2,730 | 2,603 | ||||||
|
Total Current Assets |
63,751 | 61,916 | ||||||
|
Property, Equipment and Improvements, Net |
7,359 | 7,570 | ||||||
|
Goodwill, Intangibles and Other Assets |
27,967 | 27,700 | ||||||
|
Total Assets |
$ | 99,077 | $ | 97,186 | ||||
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
||||||||
|
Current Liabilities: |
||||||||
|
Accounts Payable |
$ | 7,545 | $ | 8,787 | ||||
|
Accrued Compensation and Related Benefits |
1,694 | 2,413 | ||||||
|
Accrued Expenses and Other Current Liabilities |
2,840 | 3,039 | ||||||
|
Total Current Liabilities |
12,079 | 14,239 | ||||||
|
Deferred Income Taxes and Other Non-Current Liabilities |
3,905 | 3,898 | ||||||
|
Total Liabilities |
15,984 | 18,137 | ||||||
|
Shareholders' Equity: |
||||||||
|
Common Stock |
1,989 | 1,966 | ||||||
|
Capital in Excess of Par Value |
181,312 | 180,211 | ||||||
|
Accumulated Deficit |
(80,743 | ) | (82,894 | ) | ||||
|
Accumulated Other Comprehensive Loss |
(859 | ) | (1,611 | ) | ||||
|
Treasury Stock |
(18,469 | ) | (18,469 | ) | ||||
|
Total Ultralife Equity |
83,230 | 79,203 | ||||||
|
Non-Controlling Interest |
(137 | ) | (154 | ) | ||||
|
Total Shareholders’ Equity |
83,093 | 79,049 | ||||||
|
Total Liabilities and Shareholders' Equity |
$ | 99,077 | $ | 97,186 | ||||
|
ULTRALIFE CORPORATION AND SUBSIDIARIES |
||||||
|
CONSOLIDATED STATEMENTS OF INCOME (In Thousands Except Per Share Amounts) |
||||||
|
(Unaudited) |
|
Three Month Periods Ended |
||||||||
|
April 1, |
April 2, |
|||||||
|
2018 |
2017 |
|||||||
|
Revenues: |
||||||||
|
Battery & Energy Products |
$ | 17,224 | $ | 17,479 | ||||
|
Communications Systems |
5,845 | 4,556 | ||||||
|
Total Revenues |
23,069 | 22,035 | ||||||
|
Cost of Products Sold: |
||||||||
|
Battery & Energy Products |
12,188 | 12,549 | ||||||
|
Communications Systems |
3,599 | 2,596 | ||||||
|
Total Cost of Products Sold |
15,787 | 15,145 | ||||||
|
Gross Profit |
7,282 | 6,890 | ||||||
|
Operating Expenses: |
||||||||
|
Research and Development |
1,101 | 1,138 | ||||||
|
Selling, General and Administrative |
3,825 | 3,911 | ||||||
|
Total Operating Expenses |
4,926 | 5,049 | ||||||
|
Operating Income |
2,356 | 1,841 | ||||||
|
Other Expense |
(133 | ) | (93 | ) | ||||
|
Income Before Income Tax Provision |
2,223 | 1,748 | ||||||
|
Income Tax Provision |
(55 | ) | (87 | ) | ||||
|
Net Income |
2,168 | 1,661 | ||||||
|
Net Income Attributable to Non-Controlling Interest |
(17 | ) | (6 | ) | ||||
|
Net Income Attributable to Ultralife Corporation |
$ | 2,151 | $ | 1,655 | ||||
|
Net Income Per Share Attributable to Ultralife Common Shareholders – Basic |
||||||||
| $ | 0.14 | $ | 0.11 | |||||
|
Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted |
||||||||
| $ | 0.13 | $ | 0.11 | |||||
|
Weighted Average Shares Outstanding – Basic |
15,704 | 15,412 | ||||||
|
Weighted Average Shares Outstanding – Diluted |
16,202 | 15,656 | ||||||